Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Semyon Rubinchik

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Cytokine & Growth Factor Reviews|March 21, 2008
Transformation, translation and TRAIL: an unexpected intersectionShai White-Gilbertson, Semyon Rubinchik, Christina Voelkel-Johnson
BMC Biotechnology|February 14, 2007
Novel system uses probasin-based promoter, transcriptional silencers and amplification loop to induce high-level prostate expressionJan Woraratanadharm, Semyon Rubinchik, Hong Yu, et al.
Current Treatment Options in Oncology|September 22, 2009
Human papillomavirus and oropharyngeal cancer: what you need to know in 2009M Boyd Gillespie, Semyon Rubinchik, Brian Hoel, et al.
Cancer Gene Therapy|November 8, 2003
Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vectorSemyon Rubinchik, Hong Yu, Jan Woraratanadharm, et al.
Journal of the South Carolina Medical Association (1975)|March 31, 2009
Human papillomavirus and head and neck cancer: a growing concernM Boyd Gillespie, Jake Smith, Kevin Gibbs, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 18, 2005
Bystander effect contributes to the antitumor efficacy of CaSm antisense gene therapy in a preclinical model of advanced pancreatic cancerYan Yan, Semyon Rubinchik, April L Wood, et al.
Arthritis and Rheumatism|May 18, 2004
An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in sclerodermaJaspreet Pannu, Elizabeth Gore-Hyer, Masayoshi Yamanaka, et al.
Infectious Diseases|January 11, 2018
Retinoid Expression in Onchocercal Skin Disease: Pilot StudyAnthony R Mawson, Williams H Makunde, Alan D Penman, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 25, 2005
Establishing a murine pancreatic cancer CaSm model: up-regulation of CaSm is required for the transformed phenotype of murine pancreatic adenocarcinomaYan Yan, Semyon Rubinchik, Patricia M Watson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 24, 2006
Involvement of sphingolipids in apoptin-induced cell killingXiang Liu, Youssef H Zeidan, Saeed Elojeimy, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Cytokine & Growth Factor Reviews|March 21, 2008
Transformation, translation and TRAIL: an unexpected intersectionShai White-Gilbertson, Semyon Rubinchik, Christina Voelkel-Johnson
BMC Biotechnology|February 14, 2007
Novel system uses probasin-based promoter, transcriptional silencers and amplification loop to induce high-level prostate expressionJan Woraratanadharm, Semyon Rubinchik, Hong Yu, et al.
Current Treatment Options in Oncology|September 22, 2009
Human papillomavirus and oropharyngeal cancer: what you need to know in 2009M Boyd Gillespie, Semyon Rubinchik, Brian Hoel, et al.
Cancer Gene Therapy|November 8, 2003
Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vectorSemyon Rubinchik, Hong Yu, Jan Woraratanadharm, et al.
Journal of the South Carolina Medical Association (1975)|March 31, 2009
Human papillomavirus and head and neck cancer: a growing concernM Boyd Gillespie, Jake Smith, Kevin Gibbs, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 18, 2005
Bystander effect contributes to the antitumor efficacy of CaSm antisense gene therapy in a preclinical model of advanced pancreatic cancerYan Yan, Semyon Rubinchik, April L Wood, et al.
Arthritis and Rheumatism|May 18, 2004
An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in sclerodermaJaspreet Pannu, Elizabeth Gore-Hyer, Masayoshi Yamanaka, et al.
Infectious Diseases|January 11, 2018
Retinoid Expression in Onchocercal Skin Disease: Pilot StudyAnthony R Mawson, Williams H Makunde, Alan D Penman, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 25, 2005
Establishing a murine pancreatic cancer CaSm model: up-regulation of CaSm is required for the transformed phenotype of murine pancreatic adenocarcinomaYan Yan, Semyon Rubinchik, Patricia M Watson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 24, 2006
Involvement of sphingolipids in apoptin-induced cell killingXiang Liu, Youssef H Zeidan, Saeed Elojeimy, et al.
Pageof 2